Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nls Pharmaceutics Ltd (NLSP)

Nls Pharmaceutics Ltd (NLSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,369
  • Shares Outstanding, K 11,780
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,170 K
  • 60-Month Beta -0.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.45
Trade NLSP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/03/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1112 +2.43%
on 06/10/24
0.2399 -52.52%
on 05/24/24
-0.0370 (-24.52%)
since 05/14/24
3-Month
0.1112 +2.43%
on 06/10/24
0.3800 -70.03%
on 03/20/24
-0.2210 (-65.99%)
since 03/14/24
52-Week
0.1112 +2.43%
on 06/10/24
1.5300 -92.56%
on 07/05/23
-0.8011 (-87.55%)
since 06/14/23

Most Recent Stories

More News
NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

NLSP : 0.1139 (-1.98%)
NLSPW : 0.0297 (+14.23%)
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

ZURICH, SWITZERLAND / ACCESSWIRE / May 2, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development...

NLSPW : 0.0297 (+14.23%)
NLSP : 0.1139 (-1.98%)
Why Did Bullfrog AI Stock Jump More Than 50%?

Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University.

BFRG : 2.50 (-7.40%)
SHPH : 0.4323 (-1.59%)
FREQ : 14.9800 (+5.94%)
NLSP : 0.1139 (-1.98%)
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2

ZURICH, SWITZERLAND / ACCESSWIRE / March 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development...

NLSPW : 0.0297 (+14.23%)
NLSP : 0.1139 (-1.98%)
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia

ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSP : 0.1139 (-1.98%)
NLSPW : 0.0297 (+14.23%)
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification

ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSP : 0.1139 (-1.98%)
NLSPW : 0.0297 (+14.23%)
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer

ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSP : 0.1139 (-1.98%)
NLSPW : 0.0297 (+14.23%)
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy

ZURICH, SWITZERLAND / ACCESSWIRE / June 2, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSP : 0.1139 (-1.98%)
NLSPW : 0.0297 (+14.23%)
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

NLSP : 0.1139 (-1.98%)
NLSPW : 0.0297 (+14.23%)
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSP : 0.1139 (-1.98%)
NLSPW : 0.0297 (+14.23%)

Business Summary

NLS Pharmaceutics Ltd. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of therapies for rare and complex central nervous system disorders. The company's principal product candidate includes Quilience(R). NLS Pharmaceutics Ltd. is based in Switzerland.

See More

Key Turning Points

3rd Resistance Point 0.1316
2nd Resistance Point 0.1273
1st Resistance Point 0.1206
Last Price 0.1139
1st Support Level 0.1096
2nd Support Level 0.1053
3rd Support Level 0.0986

See More

52-Week High 1.5300
Fibonacci 61.8% 0.9880
Fibonacci 50% 0.8206
Fibonacci 38.2% 0.6532
Last Price 0.1139
52-Week Low 0.1112

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar